64.44 0.00 (0.00%)
After hours: 5:00PM EDT
|Bid||62.81 x 900|
|Ask||66.09 x 1400|
|Day's Range||63.49 - 65.49|
|52 Week Range||60.23 - 117.95|
|Beta (3Y Monthly)||1.83|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 30, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||83.60|
NEW YORK, Oct. 12, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Incyte Corporation announced today that it has scheduled its third quarter 2018 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, October 30, 2018.
Interim Phase 2 results highlight the potential of pemigatinib in cholangiocarcinoma and urothelial carcinoma
The major U.S. equities were tanking Thursday, Oct. 4, after a bond selloff sent 10-year benchmark U.S. Treasury yields rising more than 3%. The Nasdaq dropped 2.05% to 7,861, while the Dow Jones Industrial Average and S&P 500 both fell less than 1% on the day.
Ionis Pharmaceuticals (IONS) develops drugs for life-threatening diseases, and it commercializes the approved products in collaboration with other pharmaceutical companies. Ionis reported revenues of $118.0 million during the second quarter for 5.0% growth in YoY (year-over-year) revenues compared to the second quarter of 2017.
In stock news today, strong showings from biotech stocks Alexion and Incyte lifted the Nasdaq 100 to a gain of nearly 1% in afternoon trading.
On September 18, Johnson & Johnson (JNJ) announced that it had submitted a new drug application to the FDA for its investigational drug, erdafitinib, for the treatment of locally advanced or metastatic UC (urothelial cancer) in patients with certain FGFR (fibroblast growth factor receptor) genetic alterations. The application is based on the findings of BLC2001, a Phase 2 study. Erdafitinib, one of the company’s key pipeline products, is expected to drive growth. The diagram below shows some of J&J’s recent pharmaceutical launches and filings expected over the next few years. In March, J&J received breakthrough therapy designation for erdafitinib from the FDA.
As discussed earlier, Sage Therapeutics (SAGE) is focused on the development of products for the treatment of life-threatening central nervous system (or CNS) disorders. The products under development include SAGE-718 and SAGE-904.
Biotechnology company Shire (SHPG) reported a 4.6% YoY (year-over-year) rise in revenue to ~$3.9 billion in the second quarter compared to $3.7 billion in the second quarter of 2017.
Incyte Corporation (NASDAQ:INCY), a large-cap worth US$14.42b, comes to mind for investors seeking a strong and reliable stock investment. Most investors favour these big stocks due to their strong balanceRead More...
WILMINGTON, Del.-- -- Directed by an Academy Award ® winning filmmaker in the documentary short subject category, “Something So Rare” chronicles the lives of four people living with MPNs, rare blood cancers MPN community encouraged to access new resources and participate in awareness initiatives in support of MPN Awareness Day Today on MPN Awareness Day and throughout September, Blood Cancer Awareness ...
WILMINGTON, Del.-- -- Study met primary and key secondary endpoints, demonstrating significant improvement from baseline in EASI score and reduced itch compared to vehicle Results presented at EADV support planned initiation of global, pivotal Phase 3 program Incyte Corporation today announced positive results from its randomized, dose-ranging, vehicle- and active-controlled Phase 2b study evaluating ...
Pipeline updates and collaborating agreement comprise some of the key developments in the biotech sector this week.
Incyte (INCY) inks an agreement with Foundation Medicine for the development of companion diagnostics (CDx) for Incy's selective FGFR Inhibitor, pemigatinib.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Stocks that hit 52-week highs Sept. 7.) Amgen, Inc. (NASDAQ: AMGN )/p BioSpecifics Technologies ...
Incyte Corporation (INCY) and Foundation Medicine, Inc., today announced that the companies have entered into an agreement for the development, regulatory support and commercialization of companion diagnostics (CDx), with an initial focus on CDx development for pemigatinib (INCB54828), Incyte’s selective FGFR1/2/3 inhibitor, in patients with cholangiocarcinoma. The initial CDx, which will include detection of activating FGFR2 translocations, is expected to be incorporated into FoundationOne®CDx, Foundation Medicine’s FDA-approved comprehensive genomic profiling (CGP) assay and broad CDx platform. “There is an urgent need for a novel, biomarker-based, targeted therapeutic approach for patients with cholangiocarcinoma.
After recording stellar gains of 4.3 percent in the week ended Aug. 31 to close the month in the green, the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) saw a moderation in momentum in the holiday-shortened ...
The following stocks are currently in the midst of strong trendsaccording to VantagePoint , an AI charting platform that uses intermarket analysis and artificial intelligence to predict future price action ...